1. Spinal and bulbar muscular atrophy Clinical trials / Disease details
Clinical trials : 18 / Drugs : 15 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05517603 (ClinicalTrials.gov) | February 28, 2023 | 23/8/2022 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients | A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, First-In-Patient Study Of AJ201 To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics In Adults With Spinal And Bulbar Muscular Atrophy (SMBA) | Spinal and Bulbar Muscular Atrophy;Kennedy's Disease | Drug: AJ201;Drug: Placebo | AnnJi Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | N/A | Male | 24 | Phase 1/Phase 2 | United States |